ABBV vs QGEN
AbbVie vs Qiagen N.V. — AI-powered side-by-side comparison
| Metric | ABBV | QGEN |
|---|
| AI Score |
69
|
71
|
| Price |
$249.34
|
$42.98
|
| P/E Ratio |
70.28×
|
22.03×
|
| ROE |
-129.2%
|
11.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
71.5%
|
61.8%
|
| Debt / Equity |
-11.93×
|
0.49×
|
| Dividend Yield |
2.7%
|
6.1%
|
| RSI (14) |
48.9
|
58.7
|
| Beta |
0.28
|
0.62
|
| Expected Upside |
—
|
+1.9%
|
AI Committee View
Current Innellis committee reasoning for ABBV versus QGEN.
QGEN leads by 2 points.
QGEN scores 71/100 (Buy) versus ABBV at 69/100 (Buy).
ABBV Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
QGEN Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.